Ventyx Biosciences (NASDAQ:VTYX - Get Free Report) announced its earnings results on Thursday. The company reported ($0.62) EPS for the quarter, topping the consensus estimate of ($0.67) by $0.05, Briefing.com reports. During the same quarter in the prior year, the firm earned ($0.68) EPS.
Ventyx Biosciences Stock Down 8.7 %
Shares of VTYX stock traded down $0.39 during trading hours on Friday, hitting $4.09. 910,758 shares of the company's stock traded hands, compared to its average volume of 1,079,995. The stock has a market cap of $288.35 million, a PE ratio of -1.24 and a beta of 0.48. Ventyx Biosciences has a 12 month low of $1.87 and a 12 month high of $40.58. The stock's 50 day simple moving average is $5.82 and its 200 day simple moving average is $4.64.
Wall Street Analysts Forecast Growth
Several analysts have recently issued reports on VTYX shares. Wells Fargo & Company raised Ventyx Biosciences from an "equal weight" rating to an "overweight" rating and increased their target price for the stock from $7.00 to $16.00 in a report on Tuesday, March 12th. Canaccord Genuity Group cut their price target on shares of Ventyx Biosciences from $16.00 to $15.00 and set a "buy" rating for the company in a report on Wednesday, March 13th. Oppenheimer upgraded shares of Ventyx Biosciences from a "market perform" rating to an "outperform" rating and set a $12.00 price objective for the company in a research report on Tuesday, March 12th. Finally, Lifesci Capital raised Ventyx Biosciences from a "market perform" rating to an "outperform" rating in a report on Wednesday, February 28th. Four investment analysts have rated the stock with a hold rating and five have assigned a buy rating to the company. According to MarketBeat, the stock presently has an average rating of "Moderate Buy" and an average price target of $21.75.
Get Our Latest Analysis on Ventyx Biosciences
Ventyx Biosciences Company Profile
(
Get Free Report)
Ventyx Biosciences, Inc, a clinical-stage biopharmaceutical company, develops small molecule product candidates to address a range of inflammatory diseases. The company's lead clinical product candidate is VTX958, a selective allosteric tyrosine kinase type 2 inhibitor for psoriasis, psoriatic arthritis, and Crohn's disease.
Further Reading
Before you consider Ventyx Biosciences, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Ventyx Biosciences wasn't on the list.
While Ventyx Biosciences currently has a "Moderate Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Looking to avoid the hassle of mudslinging, volatility, and uncertainty? You'd need to be out of the market, which isn’t viable. So where should investors put their money? Find out with this report.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
